Brenipatide vs Tirzepatide
A long-acting dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale. A dual GIP and GLP-1 receptor agonist — the first of the co-agonists. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Brenipatide LY3537031 | Tirzepatide | |
|---|---|---|
| Also known as | — | Mounjaro, Zepbound |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GIP/GLP-1 dual agonist (acylated peptide) | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) |
| Receptor / target | GIP + GLP-1 receptors | GIP receptor + GLP-1 receptor |
| Molecular weight | ≈4,900 Da | ~4,813.5 Da |
| Half-life | engineered for an extended dosing interval (not yet disclosed) | |
| Based on | Glucagon-like peptide-1 | Glucose-dependent insulinotropic polypeptide |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Brenipatide and Tirzepatide?
- Brenipatide is an engineered analog based on Glucagon-like peptide-1; Tirzepatide is an engineered analog based on Glucose-dependent insulinotropic polypeptide. Brenipatide signals at GIP + GLP-1 receptors; Tirzepatide signals at GIP receptor + GLP-1 receptor.
- How do the half-lives of LY3537031 and Tirzepatide compare?
- The reported circulating half-life of Brenipatide is engineered for an extended dosing interval (not yet disclosed); Tirzepatide is ~5 days (~120 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tirzepatide vs Brenipatide. Or open the interactive comparison tool to add more molecules.